What is the current stock price of DarioHealth Corp. (DRIO)?

As of the latest market data, DarioHealth Corp. (DRIO) is trading at $7.26. The stock has seen a gain of 3.27% today.

Does DarioHealth Corp. (DRIO) pay a dividend?

Based on current data, DarioHealth Corp. does not have a confirmed active dividend policy.

What is the market cap of DarioHealth Corp.?

The current market capitalization of DarioHealth Corp. (DRIO) is approximately unavailable.

DRIO

DarioHealth Corp.·Healthcare

7.26

3.272%(+0.23)

Market Closed

7.70

6.061%(+0.44)

After Hours

Last Updated: — ET

52W L: $5.9352W H: $17.74

DRIO NEWS

prnewswire.com

5d ago

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value NEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.

defenseworld.net

Apr 1

Contrasting DarioHealth (NASDAQ:DRIO) & Thermo Fisher Scientific (NYSE:TMO)

DarioHealth (NASDAQ: DRIO - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 33.4% of DarioHealth shares

defenseworld.net

Mar 21

DarioHealth Q4 Earnings Call Highlights

DarioHealth (NASDAQ: DRIO) executives highlighted record commercial momentum and continued cost reductions on the company's fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating growth through 2026. Record new agreements, but full-year revenue declined Chief Executive Officer Erez Raphael said 2025 was

seekingalpha.com

Mar 19

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

zacks.com

Mar 19

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to earnings of $0.2 per share a year ago.

prnewswire.com

Mar 19

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $ 12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectory GAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-GAAP gross margins have sustained at 80% for 2 years on the core B2B2C business Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by 28% year-over-year, from $12.4 million to $9.0 million, leading to continued improvements in operating loss for the fourth quarter and full year Pipeline of commercial opportunities grew to $122 million as of December 31 2025, based on 200+ opportunities that are B2B2C Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with 36% growth in the fourth quarter of 2025 and continued expansion expected in international markets Dario will host an investor conference call and webcast at 8:30 a.m. ET today NEW YORK, March 19, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along with strategic and commercial updates.

Company Profile

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

196

IPO Date

2016-03-14

Beta

1.28

Websitewww.mydario.com↗